Loading patent…
AssigneeUnited States of America as represented by the Secretary of the Navy and Biogen, Inc.
InventorsAllan D. Kirk, David M. Harlan, David W. Thomas, Michael Kauffman, Linda Burkly
Estimating the term…
Compositions and methods disclosed herein capitalize on the discovery that rejection of a tissue graft can be inhibited using a CD40:CD154 binding interrupter, either alone or in combination with another immunomodulator or immunosuppressor. An advantageous, synergistic combination includes a CD40:CD154 binding interrupter and a CD28 signaling interrupter. An exemplary CD40:CD154 binding interrupter is an anti-CD154 monoclonal antibody, such as an antibody having the antigen-specific binding characteristics of the 5c8 monoclonal antibody. An exemplary CD28 signaling interrupter is a CTLA4-Ig fusion protein. The disclosed compositions and methods unexpectedly can be used to prolong survival of grafted tissue in a recipient host, to reverse acute graft rejection, and to attenuate immunological consequences of the failure of grafted tissue.
A method of treating rejection of a tissue graft by a primate graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to said primate.
A method of inhibiting rejection of a tissue graft by a primate graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interruptor to said primate.
A method of reversing acute rejection of grafted tissue in a primate graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to said primate.
A method of prolonging survival of grafted tissue in a primate graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to said primate.
A method of attenuating immunological complications of failure of grafted tissue in a primate graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interruptor to said primate.
A method of delaying chronic rejection of a tissue graft by a primate graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to said primate.
A method of treating rejection of a tissue graft by a primate graft recipient, comprising the steps of:
A method of inhibiting rejection of a tissue graft by a primate graft recipient, comprising the steps of:
A method of treating rejection of a tissue graft by a primate graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to a donor tissue prior to transplanting said tissue to a primate graft recipient.
A method of treating rejection of a tissue graft by a primate graft recipient, comprising the steps of:
A method of inhibiting rejection of a tissue graft by a primate graft recipient, comprising the steps of:
A method of reversing acute rejection of grafted tissue in a primate graft recipient, comprising the step of administering an effective amount of a CD40:CD154 binding interrupter to said primate on the day on which said primate presents indicia of acute graft rejection, and on days 3, 10, 18, and 28 thereafter.
A pharmaceutical composition comprising an anti-CD40L (anti-CD154) compound selected from the group consisting of a monoclonal antibody, an antigen-binding fragment thereof or an antibody derivative, wherein said compound has the antigen-specific binding characteristics of the 5c8 monoclonal antibody produced by ATCC Accession No. HB 10916, and an immunosuppressive or immunomodulatory compound selected from the group consisting of:
A pharmaceutical composition comprising an anti-CD40L (anti-CD154) compound selected from the group consisting of a monoclonal antibody, antigen-binding fragment thereof or an antibody derivative, wherein said compound has the antigen-specific binding characteristics of the 5c8 monoclonal antibody produced by ATCC Accession No. HB 10916, and an immunosuppressive or immunomodulatory compound selected from the group consisting of tacrolimus, sirolimus, mycophenolate mofetil, mizorubine, deoxyspergualin, brequinar sodium, leflunomide, and azaspirane.
A dressing for treating or inhibiting rejection of a tissue graft by a primate graft recipient, said dressing comprising an effective amount of a CD40:CD154 binding interrupter.
An intradermal patch for treating or inhibiting rejection of a tissue graft by a primate graft recipient, said intradermal patch comprising an effective amount of a CD40:CD154 binding interrupter.
Dependencies are inferred from the claim text.